Visual Acuity

ATLANTA — A study of CSF-1 showed an improvement in near visual acuity as well as distance, according to a study presented at SECO 100.

The FDA has accepted a new drug application for CSF-1 for the treatment of presbyopia, according to a press release from Orasis Pharmaceuticals.

Four-year outcomes of the DRCR Retina Network Protocol W study showed that preventive aflibercept vs. sham treatment in eyes with moderate to severe NPDR leads to anatomic improvement but no gain in visual acuity.

A study found that more than one in four U.S. adults aged 71 years and older are visually impaired, with increasing prevalence related to older age, less education, lower income, non-white race and Hispanic ethnicity.

SAN DIEGO — Phentolamine with and without low-dose pilocarpine significantly improved distance-corrected near visual acuity without compromising distance vision, according to a poster presented at Academy 2022.

In this Healio Video Perspective, Mathew W. MacCumber, MD, PhD, discusses his poster presentation on brolucizumab treatment from the Retina Society meeting.

MONTEREY, Calif. — There is more than one way to treat neurotrophic keratopathy.

UBX1325 met safety and efficacy endpoints at 24 weeks in the phase 2 BEHOLD study in patients with diabetic macular edema, according to a press release from Unity Biotechnology.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Ran Yam, of NovaSight, discusses positive topline study data for the CureSight amblyopia therapy device.

Adolescents who identified as Black or Mexican American and those from low-income families were more likely to report poor visual function and to present with worse visual acuity, according to a study.